Welcome to our dedicated page for Tango Therapeutics SEC filings (Ticker: TNGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tango Therapeutics, Inc. filings document a clinical-stage precision oncology business and its Nasdaq-listed common stock. Current reports disclose operating and financial results, business highlights for vopimetostat and related development programs, material agreements, capital-raising arrangements such as at-the-market common stock sales, and updates to governance and executive leadership.
Proxy and compensation disclosures cover board matters, executive pay, pay-versus-performance data, equity awards, and shareholder voting matters. The company’s filings also address officer appointments and departures, separation and employment agreements, compensatory arrangements, capital structure, risk factors, and other material events affecting its biotechnology operations.
Barbara Weber, Director and Executive Chair of Tango Therapeutics, Inc., reported multiple equity transactions. She acquired 37,522 shares of common stock on February 2, 2026 through restricted stock units that vest in full on February 1, 2027, subject to continued service.
On the same date she was granted a stock option for 222,132 shares at an exercise price of $11.94 per share, vesting in 12 equal monthly installments following January 1, 2026. To satisfy tax withholding under the issuer’s sell-to-cover policy, she automatically sold 30,186 shares at a weighted average price of $12.2573 and 333 shares at $12.8971 on February 3, 2026. After these transactions, she directly owned 1,629,254 shares of common stock and 222,132 options.
Tango Therapeutics President of R&D Crystal Adam reported new equity awards and related tax sales of common stock. On February 2, 2026, she received 47,460 restricted stock units, each equal to one share, vesting 33% on February 1, 2027, 33% on February 14, 2028 and 34% on February 12, 2029, subject to continued service. She also received a stock option for 284,760 shares at an exercise price of $11.94, vesting 25% on January 1, 2027 and monthly thereafter for three years. To cover tax withholding from RSU vesting under the company’s sell-to-cover policy, she automatically sold 18,251 shares at a weighted average $12.2573 and 201 shares at a weighted average $12.8971 on February 3, 2026. After these transactions, she directly owned 187,218 common shares and 284,760 options.
The Vanguard Group reported beneficial ownership of 6,750,977 shares of Tango Therapeutics Inc common stock, representing 5.01% of the class as of 12/31/2025. Vanguard reports no sole voting or dispositive power, with shared voting power over 742,606 shares and shared dispositive power over all 6,750,977 shares.
The shares are held on behalf of Vanguard’s clients, including registered investment companies and other managed accounts, and no single other person has an interest in more than 5% of the class. Vanguard states the securities were acquired and are held in the ordinary course of business and not for changing or influencing control of Tango Therapeutics. Vanguard also notes an internal realignment effective 01/12/2026, after which certain subsidiaries or business divisions may report beneficial ownership separately.
BlackRock, Inc. reported beneficial ownership of 8,477,165 shares of Tango Therapeutics, Inc. common stock, representing 6.3% of the outstanding class as of 12/31/2025. BlackRock has sole voting power over 8,351,821 of these shares and sole dispositive power over all 8,477,165 shares, with no shared voting or dispositive authority.
The shares are held across certain BlackRock business units, and various underlying clients or beneficiaries have rights to dividends or sale proceeds, but no single other person has more than five percent of Tango's outstanding common shares. BlackRock classifies itself as a parent holding company or control person and states that the securities are held in the ordinary course of business, not for the purpose of changing or influencing control of Tango Therapeutics.
Tango Therapeutics, Inc. reported that President & CEO and director Malte Peters received new equity awards. On January 8, 2026, he was granted 350,000 restricted stock units (RSUs) of common stock at a grant price of $0.00, increasing his directly held common shares to 367,500. Each RSU represents one share of common stock and will vest over three years: 33% on February 1, 2027, 33% on February 14, 2028 and 34% on February 12, 2029, subject to continued service.
He was also granted a stock option for 1,650,000 shares of common stock with an exercise price of $11.06 per share, expiring on January 8, 2036. This option vests over four years, with 25% vesting on January 8, 2027 and the remainder vesting in 36 substantially equal monthly installments thereafter, contingent on continued service, leaving him with 1,650,000 options beneficially owned.
Tango Therapeutics, Inc. reported that its unaudited cash, cash equivalents and marketable securities totaled $343 million as of December 31, 2025, providing an early view of its year-end liquidity. The company announced a leadership transition in which Barbara Weber, M.D. retired and resigned as President and Chief Executive Officer effective January 8, 2026, and moved into the role of Executive Chair through December 31, 2026 to support an orderly handover.
On the same date, board member Malte Peters, M.D. was appointed President and Chief Executive Officer. In connection with his role, he received an option to purchase 1,650,000 shares of common stock and 350,000 restricted stock units, each subject to multi‑year vesting and continued employment. The company also furnished a press release and updated corporate presentation describing these changes.
Tango Therapeutics, Inc. entered into a new Sales Agreement with Leerink Partners LLC, establishing an at-the-market equity program under which it may sell up to $100,000,000 of its common stock from time to time. Shares may be sold through Leerink as sales agent in transactions deemed an “at the market offering” or in negotiated deals if authorized by the company. Tango will pay the agent a commission of up to 3.0% of the gross sales price of any shares sold and has provided customary indemnification rights.
The company also terminated its prior Open Market Sales Agreement with Jefferies LLC, under which it had similarly been able to sell up to $100,000,000 of common stock. The Jefferies agreement ends effective November 21, 2025, and Tango states it will not face termination penalties and will no longer offer or sell shares under the 2022 ATM program.
Tango Therapeutics, Inc. has filed a resale registration covering up to 1,732,101 shares of its common stock, all to be sold from time to time by a single selling stockholder. These shares were already issued in an October 2025 private placement at $8.66 per share, which provided Tango with $15 million in gross proceeds; the company will receive no cash from any future resales under this prospectus.
Tango is an oncology company developing targeted therapies against tumor suppressor gene loss. Lead program vopimetostat (TNG462) showed a 27% objective response rate and 6.4‑month median progression‑free survival across 94 tumor‑evaluable patients with MTAP‑deleted cancers, including a 25% response rate in second‑line pancreatic cancer and 49% in a histology‑selective cohort. Additional pipeline assets include brain‑penetrant PRMT5 inhibitor TNG456, CoREST inhibitor TNG260, and HBS1L degrader TNG961.
Tango Therapeutics (TNGX) reported a director’s Form 4 reflecting a grant of stock options for 150,000 shares at an exercise price of $8.01 on November 3, 2025.
The options expire on November 3, 2035 and vest in 48 substantially equal monthly installments over four years, with the first vesting date on December 3, 2025, subject to continuous service. After this transaction, the reporting person directly holds 150,000 derivative securities.
Tango Therapeutics (TNGX) furnished a press release covering its results of operations and financial condition for the quarter ended September 30, 2025, via an Item 2.02 Form 8‑K.
The press release is furnished, not filed, and appears as Exhibit 99.1. The report was signed by Chief Financial Officer Daniella Beckman.